Pulmonary Hypertension in Infancy and Childhood

Heart Disease

Volumn 2, Issue 5, 2000, Pages 362-368

  Mathew, Rajamma ^a   Gewitz, Michael H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; HEART DISEASE; HUMAN; INFANT; LUNG DISEASE; NEWBORN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; VASCULAR ENDOTHELIUM;

CHILD; ENDOTHELIUM, VASCULAR; HEART DISEASES; HUMAN; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; LUNG DISEASES; SUPPORT, NON-U.S. GOV'T;

EID: 0034279042     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Mathew R, Altura BM. Pulmonary Circulation. Pharmacology. In: Encyclopedia of human biology. San Diego, CA: Academic Press Inc, 1997;7:301-311.
2. Paveleski HL, Shloo BL, Pietra GG, et al. Primary pulmonary hypertension: vascular structure and responsiveness to vasodilator agents. Circulation 1989; 80:1207-1221.
3. Rich S, Brundage BB. Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment. J Am Coll Cordiol 1989;14:545-550.
4. Mathew R, Omar HA, Woolf PK, et al. Microvascular reactivity as a method of assessing clinical outcome in children with congenital heart defect s and pulmonary hypertension (abstract). Circulation 1991;84:529.
5. Lopes AA, Nair YH, Conçalves RC, et al. Endothelail cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am Heart J 2000;139:618-623.
6. Ignarro LJ, Buga GM, Woods KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84:9265-9269.
7. Nakai T, Nakayoma M, Kato R. Inhibition by by nitric oxide and nitric oxide producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur J Pharmacol 1990;198:347-353.
8. Boulanger C, Luscher TF. Release of endothelin from porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990;85:587-590.
9. Janakidevi K, Fisher MA, delVecchio PJ, et al. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 1992;263:C1295-C1301.
10. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation 1993;87:440-446.
11. Dinh-Xuan AT, Higganbottam TW, Cleland C, et al. Impairment of pulmoanry endothelium-dependent relaxation in patients with Eisenmenger's syndrome. Br J Pharmacol 1990;99:9-10.
12. Mathew R, GA Zeballos, H Tun, et al. Role of nitric oxide and endothelin 1 in monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res 1995; 30:739-749.
13. Mathew R, Gloster ES, Sundarajan T, et al. Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension. J Appl Physiol 1997;82:1493-1498.
14. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Eng J Med 1991;328:1732-1739.
15. Stelzner TJ, O'Brien RF, Yanagisawa M, et al. Increased lung endorthelin 1 production in rats with pulmonary hypertension. Am J Physiol 1992;262:L614-L620.
16. Ishikawa S, Miyauchi T, Sakai S, et al. Elevated levels of plasma endothelin 1 in young patients with pulmonary hypertension caused by congenital heart diseaseare decreased after successful surgery. J Thorac Cardiovasc Surg 1995;110: 271-273.
17. Stewart DJ, Levy RD, Cenracik P. Increased plasma endothelin 1 in pulmonary hypertension: marker or mediator of disease. Ann Intern Med 1991;114:464-469.
18. Mathew R, Fan N-Y T, Yuan N, et al. Inhibition of nitric oxide synthase enhances pulmonary vascular changes in stroke-prone spontaneously hypertensive rats. Am J Physiol 2000;1999:278:L81-L89.
19. Schuster DP, Crouch EC, Parks WC, et al. Angiotensin converting enzyme expression in primary hypertension. Am J Respir Crit Care Med 1996;154: 1087-1091.
20. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Eng J Med 1992;327:70-75.
21. Yuan JX, Aldinger AM, Juhaszova, et al. Dysfuntional voltage-gated K+ channels in pulmonary artery smooth muscle cells in patients with primary pulmonary hypertension. Circulation 1998;98:1400-1406.
22. Geiger R, Berger RM, Hess J, et al. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J Pathol 2000;191:202-207.
23. Arcot SS, Lipke DW, Gillespie MN, et al. Alterations of growth factor transcripts in rat lung during development of monocrotaline-induced pulmonary hypertension. J Biochem Pharmacol 1993;46:1086-1091.
24. McGoon MD. Prognosis and natural history. In: Primary pulmonary hypertension (lung biology in health and disease), Rubin LJ, Rich S (eds). New York, NY: Marcel Dekker, 1997;99:305-317.
25. Mathew R. Development of thepulmonary circulation:Metabolic aspects. In: Fetal and neonatal physiology. Polin RA, Fox WW (eds). Philadelphia, PA: Saunders, 1998;924-929.
26. Abeman SH, BA Chatfield, SH Hall, et al. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 1990; 259:H1921-H1927.
27. Shaul PW, MA Farrar, RR Magness. Pulmonary eNOS production is developmentally regulated in the fetus and newborn. Am J Physiol 1993;265:H1056-H1063.
28. Villenueava ME, FM Zaher, DM Svinarich, et al. Decreased gene expression of eNOS in newborn with persistent pulmonary hypertension. Ped Res 1998;44: 338-343.
29. Kumar P, Kazzi NJ, Shankaran S. Plasma immunoreactive endothelin-1 concentrations in infants with persistent pulmonary hypertension of the newborn. Am J Perinatol 1996;13:335-341.
30. Wang Y, Coceani F. Isolated pulmonary resistance vessels from fetal lambs: contractile behaviour and responses to indomethacin and endothelin. Circ Res 1990;71:320-330.
31. Black SJ, Johengen MJ, Soifer SJ. Coordinated regulation of genes of the nitric oxide and endothelin pathways during the development of pulmonary hypertension in feta lambs. Pediatr Res 1998;44:821-830.
32. Fike CD, Kaplowitz MR, Thomas CJ, et al. Chronic hypoxia decreases nitric oxide production and eNOS in newborn pigs. Am J Physiol 1998:L517-L528.
33. LeCras TD, Taylor RC, Haran MP, et al. Effects of chronic hypoxia and altered hemodynamics on eNOS expression in the adult rat lung. J Clin Invest 1998; 101:795-801.
34. Hageman JR, Adams MA, Gardner TH. Persistent pulmonary hypertension of the newborn. Trends in incidence, diagnosis and management. Am J Dis Child 1984;138:592-595.
35. Levin DL, Heymann MA, Kitterman JA, et al. Persistent pulmonary hypertension of the newborn infant. J Pediatr 1976;89:626-630.
36. Rabinovitch M. Pathophysiology of pulmonary hypertension. In: Heart disease in infants, children and adolescents, including fetus and young adults, vol. 2. Emmanoulides GC, Allen HD, Reimenschneider TA, et al (eds). Baltimore, MD: Williams & Wilkins, 1995;1659-1695.
37. Wanstall JC, Jeffery TK. Recognition and management of pulmonary hypertension. Drugs 1998;56:989-1007.
38. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical inhaled nitric oxide research group. N Eng J Med 2000;342:469-474.
39. Yuhanna IS, MacRirchie AN, Lantin-Hermoso RL, et al. NO upregulates NO synthase expression in fetal intrapulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1999;21:629-636.
40. Soditt V, Aring C, Groneck P. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn. Intensive Care Med 1997;23:1275-1278.
41. Vasotka RJ, Kashyap S, Trifilitti JR. Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. Biol Neonate 1994;66:65-70.
42. McCaffrey MJ, Bose CL, Reiter PD, et al. Effects of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. Biol Neonate 1995;67:240-245.
43. Vongapatanasin W, Brickner E, Hillis LD, et al. The Eisenmenger syndrome in adults. Ann Intern Med 1998;128:745-755.
44. Heath D, Edwards J. The pathology of hypertensive vascular disease: a description of six grades of structural changes in pulmonary arteries and special reference to congenital cardiac septal defects. Circulation 1958;18:533-547.
45. Lutz J, Gorenflo M, Habighorst M, et al. Endotheliln-1 and endothelin receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin Chem Lab Med 1999;37:423-428.
46. Rabinovitch M, Keane JK, Fellows R, et al. Quantitative analysis of the pulmonary wedge angiogram in congenital heart disease: correlation with hemodynamic data and morphometric findings in lung biopsy tissue. Circulation 1981; 63:152-164.
47. McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension.: a case series. Ann Intern Med 1999;130:740-743.
48. Ko B, Turrentine MW, Sharp TG, et al. Pulmonary hypertension after operation for congenital heart disease: analysis of risk factors and management. J Thorc Cardiovasc Surg 1996;112:1600-1609.
49. Komai H, Addatia IT, Elliott MJ, et al. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease. J Thorac Cardiovasc Surg 1993;106:473-478.
50. Turner-Gomes SO, Andrus M, Coles J, et al. Abnormalities in Von Willibrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart diseases. J Thorac cardiovasc Surg 1992;103:87-97.
51. Fukado ST, Ito T, Inoue T, et al. Continuous pulmonary perfusion during cardiopulmonary bypass prevents lung injury in infants. Ann Thorac Surg 2000; 68:602-606.
52. Russel IA, Zwass MS, Fineman JR, et al. The effects of NO on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart defect. Anesth Analg 1998;87:46-51.
53. Ivy DD, Kinsella JP, Ziegler JW, et al. Dipyridamole attenuates rebound pulmonary hypertension after inhalation nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998:875-882.
54. Prendergast B, Newby DE, Wilson LE, et al. Early therapeutic experience with the endothelin receptor blocker BQ 123 in pulmojnary hypertension after congenital heart surgery. Heart 1999;82:505-508.
55. Petossian E, Parry AJ, Reddy VM, et al. Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow. J Thorac Cardiovasc Surg 1999;117:314-323.
56. Haworth SG. Primary pulmonary hypertension in childhood. Arch Dis Child 1998;79:452-455.
57. Langleben D. Familial primary pulmonary hypertension. Chest 1994;107:13S-16S.
58. Elliott G, Alexander G, Leppert M, et al. Coancestry in apparently sporadic primary pulmonary hypertension. Chest 1995;108:973-977.
59. Lloyd JE, Primm RK, Newman JH. Familial primary pulmonary hypertension: clinical patterns. Am Rev Resp Dis 1984;129:194-197.
60. Lloyd JE, Butler MG, Faroud TM, et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995;152:93-97.
61. Nichols VH, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15:277-280.
62. Barst RJ. Primary pulmonary hypertension in children. In: Primary pulmonary hypertension (lung biology in health and disease). Rubin LJ, Rich S (eds). New York, NY: Marcel Dekker, 1997;99:179-225.
63. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-1631.
64. Voelkel NF, Tudoe RM, Bridges J, et al. Interleukin 1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 1994;11:664-675.
65. Bhargava A, Kumar A, Yuan N, et al. Monocrotaline induces interleukin-6 mRNA expression in rat lungs. Heart Disease 1999;1:126-132.
66. Okawa-Takatsuji, Aotsuko A, Uwatoko S, et al. Enhanced synthesis of cytokines by peripheral blood monocytes cultured in the presence of antibodies against U1-ribonucleoprotein and/or negatively charged molecules: implication in the pathogenesis of pulmonary hypertension in mixed connective tissue disease (MCTD). Clin Exp Immunol 1994;98:427-433.
67. François B, Simnneau G. Risk factors in primary pulmonary hypertension. In: Primary pulmonary hypertension (lung biology in health and disease). Rubin LJ, Rich S (eds). New York, NY: Marcel Dekker, 1997;99:131-149.
68. de Chadarverian JP, Lischner HW, Karmazur N, et al. Pulmonary hypertension and HIV infection: new observations and review of the syndrome. Mod Pathol 1994;7:685-689.
69. Lee SD, Shroyer KR, Markham NE, et al. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998;101:927-934.
70. Voelkel NF, Tuder RM, Weir EK. Pathophysiology of primary pulmonary hypertension:from physiology to molecular mechanisms. In: Primary pulmonary hypertension (lung biology in health and disease). Rubin LJ, Rich S (eds). New York, NY: Marcel Dekker, 1997;99:83-89.
71. Rich S, Dantzker DR, Ayers SM, et al. Primary pulmonary hypertension: a national perspective study. Ann Intern Med 1987;107:216-223.
72. Wagenvoort CA, Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 1970;42:1163-1184.
73. Barst RJ, Maislin G, Fishman AP. Vasodilatory therapy for primary pulmonary hypertension in children. Circulation 1999;99:1197-1208.
74. Sandoval J, Bauerle O, Gomez A, et al. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 1995;25:466-474.
75. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension:improved long-term effects and survival with continuous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-349.
76. Conte JV, Gaine SP, Orens JB, et al. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation. J Heart Lung Transplant 1998;17:679-685.
77. Lilienfeld DE, Rubin LJ. Mortality from primary pulmonary hypertension in the US 1979-1996. Chest 2000;117:796-800.
78. Antezana AM, Antezana G, Aparicio O, et al. Pulmonary hypertension in high altitude chronic hypoxia: response to nefedipine. Eur Respir J 1998;12:1181-1183.
79. Levin DL, Muster AJ, Pachman LM, et al. Cor pulmonale secondary to upper airway obstruction. Chest 1975;68:166-171.
80. Stevenson JG. Comparison of three Doppler ultrasound methods in theprediction of pulmonary artery pressure. J Am Soc Echo 1989;2:157-171.
81. Mikhail G, al-Kattan K, Banner N, et al. Longterm results of heart-lung transplantation for pulmonary hypertension. Transpl Proc 1997;29:633.
82. Champion HC, Bivalacqua TJ, Toyoda K, et al. In vivo gene transfer of prepro calcitonin gene retated peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in mice. Circulation 2000;101:923-930.